Transcutaneous Stimulation for Neurological Populations

December 7, 2023 updated by: Chet Moritz, University of Washington

Transcutaneous Spinal Stimulation With Intensive Gait Training for Individuals With Neurologic Conditions

The purpose of the study is to evaluate whether non-invasive stimulation over the spinal cord at the neck and/or lower back can improve walking function for people with neurologic conditions. Spinal stimulation has been used extensively for individuals with spinal cord injury, and has demonstrated improvements in function. This study will extend this work to other neurologic conditions, such as cerebral palsy and stroke, that also demonstrate similar impairments as spinal cord injury.

The primary aims of this study are to:

Aim 1: Evaluate impact of spinal stimulation on spasticity and locomotor function.

Aim 2: Investigate participant perceptions of spinal stimulation.

The investigators will be using a cross-over design study to compare intensive training only to intensive training combined with spinal stimulation. After an initial baseline period of up to 4 weeks (Phase I). Participants will have their first intervention phase of the study (Phase II). This will involve either intensive training only (Condition A) or intensive training combined with spinal stimulation (Condition B). This will be followed by a washout period with no intervention (Phase III) and then the second intervention phase (Phase IV). The second intervention phase will involve either Condition A or Condition B, whichever the participants did not received during Phase II. Phases II-IV will each last up to 8 weeks. After the intervention period is complete, the participant will be asked to come for follow-up visits up to 3 months after the intervention phases are completed (Phase V).

Study Overview

Study Type

Interventional

Enrollment (Estimated)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Siddhi R Shrivastav, BPTh, MS
  • Phone Number: 973-444-1940
  • Email: siddhis@uw.edu

Study Contact Backup

  • Name: Chet T Moritz, PhD
  • Phone Number: 206-221-2842
  • Email: ctmoritz@uw.edu

Study Locations

    • Washington
      • Seattle, Washington, United States, 98115
        • Recruiting
        • University of Washington
        • Contact:
        • Contact:
        • Principal Investigator:
          • Katherine M Steele, PhD
        • Principal Investigator:
          • Chet T Moritz, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

10 years to 70 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • have a neurologic condition
  • can walk 20 yards, with or without an assistive device
  • have stable medical condition
  • are capable of performing simple cued motor tasks and who can follow 2-3 step commands
  • have ability to attend up to 5 sessions per week physical therapy sessions and testing activities
  • have adequate social support to be able to participate in training and assessment sessions, up to 5 sessions per week, for the duration of up to 11 months within the study period.
  • who are volunteering to be involved in this study
  • can read and speak English

Exclusion Criteria:

  • have significant medical disease; including uncontrolled systemic hypertension with values above 170/100 mmHg; cardiac or pulmonary disease; uncorrected coagulation abnormalities or need for therapeutic anticoagulation.
  • have cardiovascular or musculoskeletal disease or injury that would prevent full participation in physical therapy intervention
  • have a history of uncontrolled seizures
  • have unhealed fracture or other musculoskeletal impairment that might interfere with lower extremity rehabilitation or testing activities
  • are dependent on ventilation support
  • have implanted stimulator (e.g. epidural stimulator, vagus nerve stimulator, pacemaker, cochlear implant, etc) or drug delivery device (e.g. baclofen pump)
  • have history of orthopedic surgery in lower extremities or neurosurgery that may be a confounding factor for interpretation of the results (such as tendon transfer, tendon or muscle lengthening for spasticity management, injection therapies to lower extremity muscles, etc.) in last 12 months
  • have established osteoporosis and taking medication for osteoporosis treatment.
  • have rheumatic diseases (rheumatoid arthritis, systemic lupus erythematosus, etc.)
  • have active cancer

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Intensive Training Only
Physical and gait training that targets rehabilitation of walking function.
Training that targets rehabilitation of walking function
Active Comparator: Intensive Training Combined with Spinal Stimulation
Transcutaneous spinal stimulation combined with physical and gait training that targets rehabilitation of walking function.
Training that targets rehabilitation of walking function
Non-invasive electrical stimulation of the spinal cord over the skin combined with gait training

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from baseline - Six Minute Walk Test
Time Frame: Measurements at baseline and repeated measurements once every two weeks throughout the study, an average of 10 months.
Measure of walking ability. The distance is reported in meters.
Measurements at baseline and repeated measurements once every two weeks throughout the study, an average of 10 months.
Change from baseline - Ten Meter Walk Test
Time Frame: Measurements at baseline and repeated measurements once every two weeks throughout the study, an average of 10 months.
The measure of walking ability at fast and self-selected speeds. The walking speed is reported as meters per second.
Measurements at baseline and repeated measurements once every two weeks throughout the study, an average of 10 months.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from baseline - Kinetic and kinematic gait analysis using three dimensional camera system
Time Frame: Measurements at baseline and repeated measurements once every two months throughout the study, an average of 10 months.
Measurement of leg function and walking ability. Joint angle is reported in angle degrees, and velocity is reported in meters per second. Kinematic analysis will able to used to measure gait coordination and spatiotemporal outcomes, such as step length and step time.
Measurements at baseline and repeated measurements once every two months throughout the study, an average of 10 months.
Change from baseline - Electromyography recording of lower extremity muscles
Time Frame: Measurements at baseline and repeated measurements once every two months throughout the study, an average of 10 months.
Measurement of muscle and nerve functions. The muscle activities are reported in micro-volts.
Measurements at baseline and repeated measurements once every two months throughout the study, an average of 10 months.
Change from baseline - Gait Outcomes Assessment List
Time Frame: Measurements at baseline and repeated measurements once every two months throughout the study, an average of 10 months.
The patient-reported outcome measure for ambulatory children with cerebral palsy. The Gait Outcomes Assessment List comprises 48 items distributed across 7 subscales and spans all domains of the International Classification of Functioning, Disability, and Health. The score range is between 0 and 100. The higher scores mean a better outcome.
Measurements at baseline and repeated measurements once every two months throughout the study, an average of 10 months.
Change from baseline - Timed Up and Go
Time Frame: Measurements at baseline and repeated measurements once every two months throughout the study, an average of 10 months.
Measurement of mobility and fall risk. The time to complete the test is recorded in seconds.
Measurements at baseline and repeated measurements once every two months throughout the study, an average of 10 months.
Change from baseline - Modified Ashworth and Tardieu Scales
Time Frame: Measurements at baseline and repeated measurements once every two weeks throughout the study, an average of 10 months.
Measurement of spasticity in muscles. The score range is between 0 and 5. The lower scores mean a better outcome.
Measurements at baseline and repeated measurements once every two weeks throughout the study, an average of 10 months.
Change from baseline - Patient-Reported Outcomes Measurement Information System Pediatric Profile
Time Frame: Measurements at baseline and repeated measurements once every two months throughout the study, an average of 10 months.

Includes six domains. These are depression, Anxiety, Physical Function-Mobility, Pain Interference, Fatigue, and Peer Relationships. Each domain contains 8 items, along with a single item on Pain Intensity scored between 0 to 10.

The score range for each domain is between 1 and 5. The lower scores mean a better outcome.

Measurements at baseline and repeated measurements once every two months throughout the study, an average of 10 months.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Katherine M Steele, PhD, University of Washington

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2021

Primary Completion (Estimated)

August 1, 2024

Study Completion (Estimated)

December 1, 2024

Study Registration Dates

First Submitted

July 7, 2020

First Submitted That Met QC Criteria

July 9, 2020

First Posted (Actual)

July 13, 2020

Study Record Updates

Last Update Posted (Estimated)

December 11, 2023

Last Update Submitted That Met QC Criteria

December 7, 2023

Last Verified

December 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cerebral Palsy

Clinical Trials on Gait Training

3
Subscribe